P

Pfizer

Makes cancer drugs, vaccines and other medicines

Trade Account Manager

Full-TimeUpdated on 10/23/2026Deadline 10/27/26
€59.3k - €98.8k/yr
Senior
Bachelor's, Master's, MBA
Paris, France+2 moreMore locations: Rome, Metropolitan City of Rome Capital, Italy | Madrid, Spain
HybridHybrid work; listed locations include Rome, Rives de Paris, Madrid, and Paris.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree in Life Sciences, Business Administration, Marketing, or a related field is required.
  • Six or more years of experience in pharmaceutical key account management, trade account management, or related commercial roles such as tender-focused roles.
  • Experience managing complex customer accounts and working within matrix organizations.
  • Demonstrated experience with tendering processes, contract administration, and hospital procurement environments.
  • Strong communication, negotiation, and relationship-building capabilities.
  • Ability to manage complex stakeholder environments and influence decision-making at account level.
  • Customer-centric mindset with ability to align solutions to healthcare system needs.
  • Proficiency in customer relationship management (CRM) systems and data analysis tools.
  • Fluency in English and the local market language(s) for assigned markets is required.
  • High integrity and commitment to compliance.
Responsibilities
  • Execute tender submissions and contract administration for assigned markets, supporting pricing strategies and bid governance set at cluster level.
  • Manage the end-to-end tender process at account level, including identification, preparation, submission, and follow-through, in coordination with the Tender & Contracting Specialist and using Global Tender & Contracting Solution (GTCS).
  • Track tender outcomes, maintain tender calendars, and monitor win/loss performance across assigned accounts.
  • Validate AI-generated bid packages and focus on complex, exception-heavy tenders as automation scales.
  • Manage hospital enlistment and portfolio-level opportunity management across assigned accounts.
  • Build and maintain trust-based relationships with hospital pharmacies, buying groups, group purchasing organizations (GPOs), and key procurement stakeholders across assigned accounts.
  • Serve as the central point of contact for assigned accounts, ensuring alignment and coordination across internal medical, access, marketing, and compliance teams.
  • Position Pfizer GH&B as a strategic partner by articulating value in terms of patient outcomes, supply reliability, and system efficiency.
  • Develop and execute strategic account plans aligned to cluster portfolio priorities and market-level growth opportunities.
  • Support local pricing pull-through in line with cluster pricing corridors and contracting standards.
  • Execute account-level pricing and access activities, including formulary positioning, reimbursement navigation, and contract renewal management.
  • Monitor competitive pricing dynamics and provide field intelligence to cluster Pricing and Commercial Performance functions.
  • Navigate local regulatory and reimbursement requirements for biosimilar switching protocols and hospital formulary decisions.
  • Align the portfolio to customer needs and identify and act on cross-selling and enlistment opportunities to expand the portfolio's footprint within accounts.
  • Drive biosimilar switching and portfolio pull-through by working with hospital pharmacy leads on formulary conversion and protocol adoption.
  • Share market and customer insights to inform broader cluster portfolio decisions and identify new growth opportunities.
  • Support demand planning and forecasting with the Commercial Performance team by feeding account-level intelligence into financial planning cycles.
  • Use automated tender tracking and bid tools to reduce administrative burden and increase strategic customer-facing time.
  • Adopt AI-enabled CRM tools, call planning, and personalized account outreach to improve efficiency and targeting.
  • Champion digital-first engagement models, including hybrid in-person and virtual account coverage between tender cycles.
  • Ensure responsible use of AI through appropriate governance, risk awareness, and human oversight.
Desired Qualifications
  • An MBA or advanced degree.
  • Experience in biosimilars, generics, hospital, or biopharma portfolios.
  • A background in tender-driven or contract-driven commercial environments, including hospital buying groups, GPOs, or government procurement.
  • Experience with distributor management and public-private partnership models.
  • Familiarity with AI-enabled bid automation tools and digital account engagement platforms.
  • Strong analytical, strategic thinking, and problem-solving skills.

About the company

P

Pfizer

View
Website

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.